ID   ASMT_HUMAN              Reviewed;         345 AA.
AC   P46597; B2RC33; Q16598; Q5JQ72; Q5JQ73;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   10-MAY-2017, entry version 154.
DE   RecName: Full=Acetylserotonin O-methyltransferase;
DE            EC=2.1.1.4;
DE   AltName: Full=Hydroxyindole O-methyltransferase;
DE            Short=HIOMT;
GN   Name=ASMT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1; 2 AND 3), AND TISSUE
RP   SPECIFICITY.
RX   PubMed=7989373;
RA   Rodriguez I.R., Mazuruk K., Schoen T.J., Chader G.J.;
RT   "Structural analysis of the human hydroxyindole-O-methyltransferase
RT   gene. Presence of two distinct promoters.";
RL   J. Biol. Chem. 269:31969-31977(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Pineal gland;
RX   PubMed=8397829; DOI=10.1089/dna.1993.12.715;
RA   Donohue S.J., Roseboom P.H., Illnerova H., Weller J.L., Klein D.C.;
RT   "Human hydroxyindole-O-methyltransferase: presence of LINE-1 fragment
RT   in a cDNA clone and pineal mRNA.";
RL   DNA Cell Biol. 12:715-727(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Subthalamic nucleus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   TISSUE SPECIFICITY.
RX   PubMed=8574683; DOI=10.1016/0006-8993(95)00651-6;
RA   Bernard M., Donohue S.J., Klein D.C.;
RT   "Human hydroxyindole-O-methyltransferase in pineal gland, retina and
RT   Y79 retinoblastoma cells.";
RL   Brain Res. 696:37-48(1995).
RN   [7]
RP   INDUCTION BY SERUM TREATMENT.
RX   PubMed=8842389; DOI=10.1016/0006-8993(96)00359-9;
RA   Bernard M., Voisin P., Klein D.C.;
RT   "Hydroxyindole-O-methyltransferase in Y-79 cells: regulation by
RT   serum.";
RL   Brain Res. 727:118-124(1996).
RN   [8]
RP   INDUCTION BY RETINOIC ACID.
RX   PubMed=8752109;
RA   Bernard M., Klein D.C.;
RT   "Retinoic acid increases hydroxyindole-O-methyltransferase activity
RT   and mRNA in human Y-79 retinoblastoma cells.";
RL   J. Neurochem. 67:1032-1038(1996).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) IN COMPLEXES WITH
RP   S-ADENOSYL-L-METHIONINE; N-ACETYL SEROTONIN AND ZINC IONS, CATALYTIC
RP   ACTIVITY, FUNCTION, ACTIVE SITE, CHARACTERIZATION OF ISOFORMS 1; 2 AND
RP   3, SUBUNIT, TISSUE SPECIFICITY, CHARACTERIZATION OF VARIANTS HIS-13;
RP   LYS-17; GLN-61; GLU-81; LYS-111; MET-171; GLY-210; ARG-219; LEU-243;
RP   HIS-248; MET-269; SER-273; ALA-278; ASP-288; GLN-291; PHE-298 AND
RP   MET-305, AND MUTAGENESIS OF LEU-11; THR-296 AND HIS-318.
RX   PubMed=22775292; DOI=10.1111/j.1600-079X.2012.01020.x;
RA   Botros H.G., Legrand P., Pagan C., Bondet V., Weber P.,
RA   Ben-Abdallah M., Lemiere N., Huguet G., Bellalou J., Maronde E.,
RA   Beguin P., Haouz A., Shepard W., Bourgeron T.;
RT   "Crystal structure and functional mapping of human ASMT, the last
RT   enzyme of the melatonin synthesis pathway.";
RL   J. Pineal Res. 54:46-57(2013).
RN   [10]
RP   VARIANTS ASP-288 AND PHE-298.
RX   PubMed=17957233; DOI=10.1038/sj.mp.4002069;
RA   Toma C., Rossi M., Sousa I., Blasi F., Bacchelli E., Alen R.,
RA   Vanhala R., Monaco A.P., Jarvela I., Maestrini E.;
RT   "Is ASMT a susceptibility gene for autism spectrum disorders? A
RT   replication study in European populations.";
RL   Mol. Psychiatry 12:977-979(2007).
RN   [11]
RP   VARIANTS LYS-17; GLU-81; ALA-278 AND PHE-298.
RX   PubMed=17505466; DOI=10.1038/sj.mp.4002016;
RA   Melke J., Goubran Botros H., Chaste P., Betancur C., Nygren G.,
RA   Anckarsater H., Rastam M., Stahlberg O., Gillberg I.C., Delorme R.,
RA   Chabane N., Mouren-Simeoni M.C., Fauchereau F., Durand C.M.,
RA   Chevalier F., Drouot X., Collet C., Launay J.M., Leboyer M.,
RA   Gillberg C., Bourgeron T.;
RT   "Abnormal melatonin synthesis in autism spectrum disorders.";
RL   Mol. Psychiatry 13:90-98(2008).
RN   [12]
RP   VARIANTS HIS-13; LYS-17; GLN-61; MET-171; GLY-210; ARG-219; LEU-243;
RP   SER-273; ASP-288; GLN-291 AND PHE-298.
RX   PubMed=21251267; DOI=10.1186/1471-2350-12-17;
RA   Pagan C., Botros H.G., Poirier K., Dumaine A., Jamain S., Moreno S.,
RA   de Brouwer A., Van Esch H., Delorme R., Launay J.M., Tzschach A.,
RA   Kalscheuer V., Lacombe D., Briault S., Laumonnier F., Raynaud M.,
RA   van Bon B.W., Willemsen M.H., Leboyer M., Chelly J., Bourgeron T.;
RT   "Mutation screening of ASMT, the last enzyme of the melatonin pathway,
RT   in a large sample of patients with intellectual disability.";
RL   BMC Med. Genet. 12:17-17(2011).
RN   [13]
RP   VARIANTS GLY-210 AND PHE-298.
RX   PubMed=21615493; DOI=10.1111/j.1600-079X.2011.00902.x;
RA   Chaste P., Clement N., Botros H.G., Guillaume J.L., Konyukh M.,
RA   Pagan C., Scheid I., Nygren G., Anckarsater H., Rastam M.,
RA   Stahlberg O., Gillberg I.C., Melke J., Delorme R., Leblond C.,
RA   Toro R., Huguet G., Fauchereau F., Durand C., Boudarene L.,
RA   Serrano E., Lemiere N., Launay J.M., Leboyer M., Jockers R.,
RA   Gillberg C., Bourgeron T.;
RT   "Genetic variations of the melatonin pathway in patients with
RT   attention-deficit and hyperactivity disorders.";
RL   J. Pineal Res. 51:394-399(2011).
RN   [14]
RP   VARIANTS GLN-61; LYS-111; ARG-219; LEU-243; HIS-248; SER-273; ASP-288;
RP   GLN-291; PHE-298 AND MET-305.
RX   PubMed=22694957; DOI=10.1093/hmg/dds227;
RA   Etain B., Dumaine A., Bellivier F., Pagan C., Francelle L.,
RA   Goubran-Botros H., Moreno S., Deshommes J., Moustafa K., Le Dudal K.,
RA   Mathieu F., Henry C., Kahn J.P., Launay J.M., Muhleisen T.W.,
RA   Cichon S., Bourgeron T., Leboyer M., Jamain S.;
RT   "Genetic and functional abnormalities of the melatonin biosynthesis
RT   pathway in patients with bipolar disorder.";
RL   Hum. Mol. Genet. 21:4030-4037(2012).
RN   [15]
RP   VARIANTS LYS-17; TRP-115; SER-151; ILE-166; GLY-179; MET-211; MET-217
RP   AND LEU-243.
RX   PubMed=23349736; DOI=10.1371/journal.pone.0053727;
RA   Wang L., Li J., Ruan Y., Lu T., Liu C., Jia M., Yue W., Liu J.,
RA   Bourgeron T., Zhang D.;
RT   "Sequencing ASMT identifies rare mutations in Chinese Han patients
RT   with autism.";
RL   PLoS ONE 8:E53727-E53727(2013).
CC   -!- FUNCTION: Isoform 1 catalyzes the transfer of a methyl group onto
CC       N-acetylserotonin, producing melatonin (N-acetyl-5-
CC       methoxytryptamine). Isoform 2 and isoform 3 lack enzyme activity.
CC       {ECO:0000269|PubMed:22775292}.
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + N-acetylserotonin =
CC       S-adenosyl-L-homocysteine + melatonin.
CC       {ECO:0000269|PubMed:22775292}.
CC   -!- PATHWAY: Aromatic compound metabolism; melatonin biosynthesis;
CC       melatonin from serotonin: step 1/2.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:22775292}.
CC   -!- INTERACTION:
CC       Self; NbExp=3; IntAct=EBI-6502097, EBI-6502097;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P46597-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P46597-2; Sequence=VSP_004285;
CC       Name=3;
CC         IsoId=P46597-3; Sequence=VSP_004284;
CC         Note=Includes part of a LINE-1 element. Ref.1
CC         (AAA58582/AAA58583/AAA75290), Ref.2 (AAA17020) and Ref.3
CC         (BAG37430) sequences are in conflict in position: 190:W->R.
CC         {ECO:0000305};
CC   -!- TISSUE SPECIFICITY: Expressed in the pineal gland (at protein
CC       level). In the retina, very low expression is found at the mRNA
CC       level (PubMed:7989373), and not at the protein level
CC       (PubMed:8574683). {ECO:0000269|PubMed:22775292,
CC       ECO:0000269|PubMed:7989373, ECO:0000269|PubMed:8574683}.
CC   -!- INDUCTION: By all-trans-, 9-cis- and 13-cis-retinoic acid and by
CC       serum treatment, following starvation, in the retinoblastoma cell
CC       line Y79. {ECO:0000269|PubMed:8752109,
CC       ECO:0000269|PubMed:8842389}.
CC   -!- MISCELLANEOUS: The gene coding for this protein is located in the
CC       pseudoautosomal region 1 (PAR1) of X and Y chromosomes.
CC   -!- SIMILARITY: Belongs to the class I-like SAM-binding
CC       methyltransferase superfamily. Cation-independent O-
CC       methyltransferase family. {ECO:0000255|PROSITE-ProRule:PRU01020}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=5-hydroxyindole-O-
CC       methyltransferase entry;
CC       URL="https://en.wikipedia.org/wiki/5-hydroxyindole-O-methyltransferase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U11098; AAA75291.1; -; Genomic_DNA.
DR   EMBL; U11089; AAA75291.1; JOINED; Genomic_DNA.
DR   EMBL; U11093; AAA75291.1; JOINED; Genomic_DNA.
DR   EMBL; U11094; AAA75291.1; JOINED; Genomic_DNA.
DR   EMBL; U11095; AAA75291.1; JOINED; Genomic_DNA.
DR   EMBL; U11096; AAA75291.1; JOINED; Genomic_DNA.
DR   EMBL; U11092; AAA75291.1; JOINED; Genomic_DNA.
DR   EMBL; U11097; AAA75291.1; JOINED; Genomic_DNA.
DR   EMBL; U11098; AAA75289.1; -; Genomic_DNA.
DR   EMBL; U11089; AAA75289.1; JOINED; Genomic_DNA.
DR   EMBL; U11093; AAA75289.1; JOINED; Genomic_DNA.
DR   EMBL; U11094; AAA75289.1; JOINED; Genomic_DNA.
DR   EMBL; U11095; AAA75289.1; JOINED; Genomic_DNA.
DR   EMBL; U11096; AAA75289.1; JOINED; Genomic_DNA.
DR   EMBL; U11097; AAA75289.1; JOINED; Genomic_DNA.
DR   EMBL; U11098; AAA75290.1; -; Genomic_DNA.
DR   EMBL; U11089; AAA75290.1; JOINED; Genomic_DNA.
DR   EMBL; U11093; AAA75290.1; JOINED; Genomic_DNA.
DR   EMBL; U11094; AAA75290.1; JOINED; Genomic_DNA.
DR   EMBL; U11095; AAA75290.1; JOINED; Genomic_DNA.
DR   EMBL; U11096; AAA75290.1; JOINED; Genomic_DNA.
DR   EMBL; U11092; AAA75290.1; JOINED; Genomic_DNA.
DR   EMBL; U11097; AAA75290.1; JOINED; Genomic_DNA.
DR   EMBL; U11090; AAA58582.1; -; mRNA.
DR   EMBL; U11091; AAA58583.1; -; mRNA.
DR   EMBL; M83779; AAA17020.1; -; mRNA.
DR   EMBL; AK314922; BAG37430.1; -; mRNA.
DR   EMBL; AL683807; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC001620; AAH01620.1; -; mRNA.
DR   CCDS; CCDS14117.1; -. [P46597-3]
DR   CCDS; CCDS55364.1; -. [P46597-2]
DR   PIR; I37463; I37463.
DR   RefSeq; NP_001164509.1; NM_001171038.1. [P46597-3]
DR   RefSeq; NP_001164510.1; NM_001171039.1. [P46597-2]
DR   RefSeq; NP_004034.2; NM_004043.2. [P46597-3]
DR   UniGene; Hs.522572; -.
DR   PDB; 4A6D; X-ray; 2.40 A; A=1-345.
DR   PDB; 4A6E; X-ray; 2.70 A; A=1-345.
DR   PDBsum; 4A6D; -.
DR   PDBsum; 4A6E; -.
DR   ProteinModelPortal; P46597; -.
DR   SMR; P46597; -.
DR   DrugBank; DB01065; Melatonin.
DR   BioMuta; ASMT; -.
DR   DMDM; 1170276; -.
DR   PeptideAtlas; P46597; -.
DR   PRIDE; P46597; -.
DR   DNASU; 438; -.
DR   Ensembl; ENST00000381229; ENSP00000370627; ENSG00000196433. [P46597-1]
DR   Ensembl; ENST00000381233; ENSP00000370631; ENSG00000196433. [P46597-2]
DR   Ensembl; ENST00000381241; ENSP00000370639; ENSG00000196433. [P46597-3]
DR   GeneID; 438; -.
DR   KEGG; hsa:438; -.
DR   UCSC; uc010ncy.4; human. [P46597-1]
DR   CTD; 438; -.
DR   DisGeNET; 438; -.
DR   GeneCards; ASMT; -.
DR   HGNC; HGNC:750; ASMT.
DR   MIM; 300015; gene.
DR   MIM; 402500; gene.
DR   neXtProt; NX_P46597; -.
DR   OpenTargets; ENSG00000196433; -.
DR   PharmGKB; PA25049; -.
DR   GeneTree; ENSGT00530000064032; -.
DR   HOGENOM; HOG000247024; -.
DR   HOVERGEN; HBG001526; -.
DR   InParanoid; P46597; -.
DR   KO; K00543; -.
DR   OMA; GTWIKLE; -.
DR   PhylomeDB; P46597; -.
DR   TreeFam; TF314574; -.
DR   BioCyc; MetaCyc:HS09884-MONOMER; -.
DR   BRENDA; 2.1.1.4; 2681.
DR   Reactome; R-HSA-209931; Serotonin and melatonin biosynthesis.
DR   UniPathway; UPA00837; UER00815.
DR   GeneWiki; Acetylserotonin_O-methyltransferase; -.
DR   GenomeRNAi; 438; -.
DR   PRO; PR:P46597; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000196433; -.
DR   ExpressionAtlas; P46597; baseline and differential.
DR   Genevisible; P46597; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0017096; F:acetylserotonin O-methyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0008171; F:O-methyltransferase activity; TAS:ProtInc.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0008172; F:S-methyltransferase activity; TAS:Reactome.
DR   GO; GO:0046219; P:indolalkylamine biosynthetic process; TAS:Reactome.
DR   GO; GO:0030187; P:melatonin biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006412; P:translation; TAS:ProtInc.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR031725; ASMT_dimerisation.
DR   InterPro; IPR016461; O-MeTrfase_COMT.
DR   InterPro; IPR001077; O_MeTrfase_2.
DR   InterPro; IPR029063; SAM-dependent_MTases.
DR   InterPro; IPR011991; WHTH_DNA-bd_dom.
DR   Pfam; PF16864; Dimerisation2; 1.
DR   Pfam; PF00891; Methyltransf_2; 1.
DR   PIRSF; PIRSF005739; O-mtase; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   SUPFAM; SSF53335; SSF53335; 1.
DR   PROSITE; PS51683; SAM_OMT_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Melatonin biosynthesis; Methyltransferase; Polymorphism;
KW   Reference proteome; S-adenosyl-L-methionine; Transferase.
FT   CHAIN         1    345       Acetylserotonin O-methyltransferase.
FT                                /FTId=PRO_0000083982.
FT   REGION      235    237       S-adenosyl-L-methionine binding.
FT   ACT_SITE    255    255       Proton donor/acceptor.
FT                                {ECO:0000305|PubMed:22775292}.
FT   BINDING     147    147       S-adenosyl-L-methionine.
FT   BINDING     164    164       S-adenosyl-L-methionine.
FT   BINDING     210    210       S-adenosyl-L-methionine.
FT   BINDING     252    252       S-adenosyl-L-methionine.
FT   BINDING     256    256       Substrate.
FT   BINDING     302    302       Substrate.
FT   BINDING     306    306       Substrate.
FT   VAR_SEQ     188    188       G -> GTWIKLETIILSKLSQGQKTKHRVFSLIG (in
FT                                isoform 3). {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:8397829}.
FT                                /FTId=VSP_004284.
FT   VAR_SEQ     189    235       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_004285.
FT   VARIANT      13     13       N -> H (polymorphism; no effect on enzyme
FT                                activity; dbSNP:rs121918819).
FT                                {ECO:0000269|PubMed:21251267,
FT                                ECO:0000269|PubMed:22775292}.
FT                                /FTId=VAR_069111.
FT   VARIANT      17     17       N -> K (functional polymorphism; nearly
FT                                abolishes enzyme activity;
FT                                dbSNP:rs17149149).
FT                                {ECO:0000269|PubMed:17505466,
FT                                ECO:0000269|PubMed:21251267,
FT                                ECO:0000269|PubMed:22775292,
FT                                ECO:0000269|PubMed:23349736}.
FT                                /FTId=VAR_045991.
FT   VARIANT      61     61       E -> Q (functional polymorphism; reduced
FT                                enzyme activity; dbSNP:rs121918823).
FT                                {ECO:0000269|PubMed:21251267,
FT                                ECO:0000269|PubMed:22694957,
FT                                ECO:0000269|PubMed:22775292}.
FT                                /FTId=VAR_069112.
FT   VARIANT      81     81       K -> E (polymorphism; no effect on enzyme
FT                                activity; dbSNP:rs117343570).
FT                                {ECO:0000269|PubMed:17505466,
FT                                ECO:0000269|PubMed:22775292}.
FT                                /FTId=VAR_069113.
FT   VARIANT     111    111       R -> K (polymorphism; no effect on enzyme
FT                                activity). {ECO:0000269|PubMed:22694957,
FT                                ECO:0000269|PubMed:22775292}.
FT                                /FTId=VAR_069114.
FT   VARIANT     115    115       R -> W (in dbSNP:rs201053197).
FT                                {ECO:0000269|PubMed:23349736}.
FT                                /FTId=VAR_069115.
FT   VARIANT     151    151       G -> S (in dbSNP:rs192710293).
FT                                {ECO:0000269|PubMed:23349736}.
FT                                /FTId=VAR_069116.
FT   VARIANT     166    166       V -> I (in dbSNP:rs373339042).
FT                                {ECO:0000269|PubMed:23349736}.
FT                                /FTId=VAR_069117.
FT   VARIANT     171    171       V -> M (functional polymorphism; nearly
FT                                abolishes enzyme activity;
FT                                dbSNP:rs121918820).
FT                                {ECO:0000269|PubMed:21251267,
FT                                ECO:0000269|PubMed:22775292}.
FT                                /FTId=VAR_069118.
FT   VARIANT     179    179       V -> G. {ECO:0000269|PubMed:23349736}.
FT                                /FTId=VAR_069119.
FT   VARIANT     210    210       D -> G (functional polymorphism; nearly
FT                                abolishes enzyme activity;
FT                                dbSNP:rs121918824).
FT                                {ECO:0000269|PubMed:21251267,
FT                                ECO:0000269|PubMed:21615493,
FT                                ECO:0000269|PubMed:22775292}.
FT                                /FTId=VAR_069120.
FT   VARIANT     211    211       I -> M (in dbSNP:rs201316181).
FT                                {ECO:0000269|PubMed:23349736}.
FT                                /FTId=VAR_069121.
FT   VARIANT     217    217       T -> M (in dbSNP:rs148036160).
FT                                {ECO:0000269|PubMed:23349736}.
FT                                /FTId=VAR_069122.
FT   VARIANT     219    219       K -> R (polymorphism; no effect on enzyme
FT                                activity; dbSNP:rs121918825).
FT                                {ECO:0000269|PubMed:21251267,
FT                                ECO:0000269|PubMed:22694957,
FT                                ECO:0000269|PubMed:22775292}.
FT                                /FTId=VAR_069123.
FT   VARIANT     243    243       P -> L (functional polymorphism; reduced
FT                                enzyme activity; dbSNP:rs121918826).
FT                                {ECO:0000269|PubMed:21251267,
FT                                ECO:0000269|PubMed:22694957,
FT                                ECO:0000269|PubMed:22775292,
FT                                ECO:0000269|PubMed:23349736}.
FT                                /FTId=VAR_069124.
FT   VARIANT     248    248       Y -> H (functional polymorphism; nearly
FT                                abolishes enzyme activity).
FT                                {ECO:0000269|PubMed:22694957,
FT                                ECO:0000269|PubMed:22775292}.
FT                                /FTId=VAR_069125.
FT   VARIANT     269    269       I -> M (functional polymorphism; reduced
FT                                enzyme activity; dbSNP:rs146121655).
FT                                {ECO:0000269|PubMed:22775292}.
FT                                /FTId=VAR_069126.
FT   VARIANT     273    273       C -> S (functional polymorphism; reduced
FT                                enzyme activity; dbSNP:rs121918827).
FT                                {ECO:0000269|PubMed:21251267,
FT                                ECO:0000269|PubMed:22694957,
FT                                ECO:0000269|PubMed:22775292}.
FT                                /FTId=VAR_069127.
FT   VARIANT     278    278       G -> A (functional polymorphism; reduced
FT                                enzyme activity).
FT                                {ECO:0000269|PubMed:17505466,
FT                                ECO:0000269|PubMed:22775292}.
FT                                /FTId=VAR_069128.
FT   VARIANT     288    288       E -> D (polymorphism; no effect on enzyme
FT                                activity; dbSNP:rs121918821).
FT                                {ECO:0000269|PubMed:17957233,
FT                                ECO:0000269|PubMed:21251267,
FT                                ECO:0000269|PubMed:22694957,
FT                                ECO:0000269|PubMed:22775292}.
FT                                /FTId=VAR_069129.
FT   VARIANT     291    291       R -> Q (functional polymorphism; nearly
FT                                abolishes enzyme activity;
FT                                dbSNP:rs121918828).
FT                                {ECO:0000269|PubMed:21251267,
FT                                ECO:0000269|PubMed:22694957,
FT                                ECO:0000269|PubMed:22775292}.
FT                                /FTId=VAR_069130.
FT   VARIANT     298    298       L -> F (functional polymorphism; nearly
FT                                abolishes enzyme activity;
FT                                dbSNP:rs121918822).
FT                                {ECO:0000269|PubMed:17505466,
FT                                ECO:0000269|PubMed:17957233,
FT                                ECO:0000269|PubMed:21251267,
FT                                ECO:0000269|PubMed:21615493,
FT                                ECO:0000269|PubMed:22694957,
FT                                ECO:0000269|PubMed:22775292}.
FT                                /FTId=VAR_069131.
FT   VARIANT     305    305       V -> M (functional polymorphism; reduced
FT                                enzyme activity).
FT                                {ECO:0000269|PubMed:22694957,
FT                                ECO:0000269|PubMed:22775292}.
FT                                /FTId=VAR_069132.
FT   MUTAGEN      11     11       L->F: Reduced enzyme activity.
FT                                {ECO:0000269|PubMed:22775292}.
FT   MUTAGEN      31     31       L->H: No effect on enzyme activity.
FT   MUTAGEN     296    296       T->M: Nearly abolishes enzyme activity.
FT                                {ECO:0000269|PubMed:22775292}.
FT   MUTAGEN     318    318       H->D: Reduced enzyme activity.
FT                                {ECO:0000269|PubMed:22775292}.
FT   CONFLICT    302    302       N -> S (in Ref. 3; BAG37430).
FT                                {ECO:0000305}.
FT   HELIX         7     31       {ECO:0000244|PDB:4A6D}.
FT   HELIX        33     39       {ECO:0000244|PDB:4A6D}.
FT   STRAND       40     42       {ECO:0000244|PDB:4A6D}.
FT   HELIX        46     53       {ECO:0000244|PDB:4A6D}.
FT   HELIX        57     69       {ECO:0000244|PDB:4A6D}.
FT   STRAND       72     78       {ECO:0000244|PDB:4A6D}.
FT   STRAND       81     86       {ECO:0000244|PDB:4A6D}.
FT   HELIX        88     94       {ECO:0000244|PDB:4A6D}.
FT   HELIX       103    111       {ECO:0000244|PDB:4A6D}.
FT   HELIX       113    117       {ECO:0000244|PDB:4A6D}.
FT   HELIX       120    126       {ECO:0000244|PDB:4A6D}.
FT   HELIX       131    135       {ECO:0000244|PDB:4A6D}.
FT   HELIX       142    146       {ECO:0000244|PDB:4A6D}.
FT   HELIX       150    161       {ECO:0000244|PDB:4A6D}.
FT   HELIX       164    173       {ECO:0000244|PDB:4A6D}.
FT   HELIX       177    179       {ECO:0000244|PDB:4A6D}.
FT   STRAND      181    186       {ECO:0000244|PDB:4A6D}.
FT   HELIX       192    200       {ECO:0000244|PDB:4A6D}.
FT   STRAND      205    210       {ECO:0000244|PDB:4A6D}.
FT   HELIX       212    221       {ECO:0000244|PDB:4A6D}.
FT   STRAND      229    235       {ECO:0000244|PDB:4A6D}.
FT   TURN        237    239       {ECO:0000244|PDB:4A6D}.
FT   STRAND      246    253       {ECO:0000244|PDB:4A6D}.
FT   HELIX       254    256       {ECO:0000244|PDB:4A6D}.
FT   HELIX       259    272       {ECO:0000244|PDB:4A6D}.
FT   STRAND      278    283       {ECO:0000244|PDB:4A6D}.
FT   HELIX       294    305       {ECO:0000244|PDB:4A6D}.
FT   STRAND      306    308       {ECO:0000244|PDB:4A6D}.
FT   HELIX       314    324       {ECO:0000244|PDB:4A6D}.
FT   STRAND      327    332       {ECO:0000244|PDB:4A6D}.
FT   STRAND      335    337       {ECO:0000244|PDB:4A6D}.
FT   STRAND      339    344       {ECO:0000244|PDB:4A6D}.
SQ   SEQUENCE   345 AA;  38453 MW;  187A375E1E2940B7 CRC64;
     MGSSEDQAYR LLNDYANGFM VSQVLFAACE LGVFDLLAEA PGPLDVAAVA AGVRASAHGT
     ELLLDICVSL KLLKVETRGG KAFYRNTELS SDYLTTVSPT SQCSMLKYMG RTSYRCWGHL
     ADAVREGRNQ YLETFGVPAE ELFTAIYRSE GERLQFMQAL QEVWSVNGRS VLTAFDLSVF
     PLMCDLGGGA GALAKECMSL YPGCKITVFD IPEVVWTAKQ HFSFQEEEQI DFQEGDFFKD
     PLPEADLYIL ARVLHDWADG KCSHLLERIY HTCKPGGGIL VIESLLDEDR RGPLLTQLYS
     LNMLVQTEGQ ERTPTHYHML LSSAGFRDFQ FKKTGAIYDA ILARK
//
